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Abstract
Background: Little is known about the proportion of pediatric pandemic A/H1N1/2009 influenza cases who
showed seroconversion, the magnitude of this seroconversion, or the factors that can affect the antibody level
evoked by the pandemic A/H1N1/2009 influenza. Aims of this study were to analyse antibody responses and the
factors associated with high antibody titres in a cohort of children with naturally acquired A/H1N1/2009 influenza
infection confirmed by reverse-transcriptase polymerase chain reaction (RT-PCR).
Results: Demographic, clinical and virologic data were collected from 69 otherwise healthy children with
pandemic A/H1N1/2009 influenza (27 females, mean age ± SD: 5.01 ± 4.55 years). Their antibody levels against
pandemic A/H1N1/2009 and seasonal A/H1N1 influenza viruses were evaluated by measuring hemagglutination-
inhibiting antibodies using standard assays. Sixty-four patients (92.8%) with pandemic A/H1N1/2009 influenza had
A/H1N1/2009 antibody levels of ≥40, whereas only 28/69 (40.6%) were seroprotected against seasonal A/H1N1
influenza virus. Those who were seroprotected against seasonal A/H1N1 virus were significantly older, significantly
more often hospitalised, had a diagnosis of pneumonia significantly more frequently, and were significantly more
often treated with oseltamivir than those who were not seroprotected (p < 0.05). The children with the most
severe disease (assessed on the basis of a need for hospitalisation and a diagnosis of pneumonia) had the highest
antibody response against pandemic A/H1N1/2009 influenza virus.
Conclusions: Otherwise healthy children seem to show seroprotective antibody titres after natural infection with
pandemic A/H1N1/2009 influenza virus. The strength of the immune response seems to be related to the severity
of the disease, but not to previous seasonal A/H1N1 influenza immunity.
Keywords: Children, Immune response, Influenza, Pandemic A/H1N1/2009 influenza virus, Pediatric infectious
diseases
Background
An A/H1N1 quadruple reassortant influenza virus (A/
H1N1/2009) of swine origin has recently arisen from a
subtype A/H1N1 influenza virus that was already ende-
mic in humans. It caused a pandemic [1], with a very
high disease burden among children and young adults:
up to 50% showed signs of infection, against 10% of the
adult population [2,3]. Severe disease and hospitalisa-
tions were also associated with younger age groups [4,5].
Serological analyses of pre-pandemic serum samples
showed that a number of adult and elderly subjects had
higher levels of cross-reactive A/H1N1/2009 antibodies
than young adults and children (the older the patient, the
higher the levels) [2,6,7]. It has been suggested that the
age-related differences in the frequency and severity of
pandemic influenza infection were due to multiple expo-
sures to older viruses with similar B cell epitopes, and the
conservation of T cell epitopes between the seasonal
A/H1N1 and pandemic A/H1N1/2009 viruses [8,9].
However, very few pediatric data are available, and lit-
tle is known about the proportion of pediatric pandemic
A/H1N1/2009 influenza cases showing seroconversion,
the magnitude of this seroconversion, or the factors
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influencing the antibody levels evoked by the pandemic
A/H1N1/2009 influenza virus.
The aim of this study was to contribute towards filling
these gaps by analysing antibody responses and the fac-
tors associated with high antibody titres in a cohort of
children with naturally acquired pandemic A/H1N1/
2009 influenza infection confirmed by reverse-transcrip-
tase polymerase chain reaction (RT-PCR).
Results
Sixty-nine of the 101 initially enrolled children (68.3%;
27 females; mean age 5.01 ± 4.55 years) were positive
for pandemic A/H1N1/2009 influenza virus assessed by
RT-PCR and were included in the final analysis. Table 1
shows their demographic and clinical characteristics.
Sixty-four (92.8%) had pandemic A/H1N1/2009 antibody
levels of ≥40, whereas only 28 (40.6%) were seropro-
tected against seasonal A/H1N1 virus. Those who were
seroprotected against seasonal A/H1N1 influenza virus
were significantly older, significantly more often hospita-
lised, had a diagnosis of pneumonia significantly more
frequently, and were significantly more often treated
with oseltamivir than those who were not seroprotected.
There were no differences in the geometric mean titres
(GMTs) of pandemic A/H1N1/2009 antibodies or viral
load between the children who were seroprotected
against seasonal A/H1N1 influenza virus and those who
were not.
Table 2 shows that high pandemic A/H1N1/2009 anti-
body titres (≥160, detected in 26 patients) were not
associated with age, gender, viral load or oseltamivir
treatment. Univariate analysis showed that the patients
with the highest pandemic A/H1N1/2009 antibody titres
were significantly less often seroprotected against seaso-
nal A/H1N1 influenza virus, but this association was not
confirmed by the multivariate analysis. On the contrary,
the children with the most severe disease (as evaluated
on the basis of the need for hospitalisation and a diag-
nosis of pneumonia) had the highest antibody response
to pandemic A/H1N1/2009 influenza virus at both uni-
variate and multivariate analysis.
Discussion
The findings of this study clearly show that otherwise
healthy children can produce a protective immune
response when they are infected by the recent pandemic
A/H1N1/2009 influenza virus. They are in line with
those of authors studying seasonal influenza viruses
[10,11], and confirm that most children, including those
aged less than two years, seem to have an immune sys-
tem that can efficiently face influenza virus infection.
More than 90% of the convalescent children in our
population had a pandemic A/H1N1/2009 antibody
level of ≥40 about four weeks after the onset of their ill-
ness. Both the seroconversion rate and the magnitude of
antibody responses of our healthy children were similar
to those reported by others studying convalescent sera
obtained from older patients [2,12-14].
However, despite these similarities, some of our find-
ings are quite different from those found in adult and
Table 1 Demographic and clinical characteristics of children with pandemic A/H1N1/2009 influenza infection
Variables Seroprotection against seasonal A/H1N1
influenza virus (n = 28)
Absence of seroprotection against seasonal A/H1N1
influenza virus (n = 41)
Age
<2 yrs 2 (7.1)* 18 (43.9)
2-5 yrs 8 (28.6) 13 (31.7)
>5 yrs 18 (64.3)* 10 (24.4)
Mean age ± SD 5.03 ± 4.38* 2.38 ± 4.66
Gender, females 9 (32.1) 18 (43.9)
Previous influenza vaccination 0 (0.0) 0 (0.0)
Hospitalisation 9 (32.1)* 4 (9.8)
Diagnosis
Pneumonia 15 (53.6)* 10 (24.4)
Upper respiratory tract Infection 13 (46.4)* 31 (75.6)
Antibodies against pandemic A/H1N1/
2009 influenza virus
≥40 27 (96.4) 37 (90.2)
GMT 163.33 211.46
Viral load, log10 cp/mL
Mean value ± SD 7.71 ± 1.69 7.70 ± 1.64
Treated with oseltamivir 15 (53.6)* 10 (24.4)
GMT geometric mean titres, SD standard deviation. Numbers with percentages in parenthesis. *p <0.05 vs absence of seroprotection against seasonal A/H1N1
influenza virus
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elderly subjects: those previously exposed to seasonal A/
H1N1 influenza viruses experienced significantly less
severe influenza [2-5], whereas the rates of hospitalisa-
tion and a diagnosis of pneumonia were significantly
higher in our children with protective antibodies against
seasonal A/H1N1 influenza virus than in those without.
Moreover, on the basis of what has been demonstrated
in experimental animals, we expected to find a stronger
immune response to the pandemic A/H1N1/2009 influ-
enza virus in children who had previously been affected
by seasonal A/H1N1 influenza. It has been found that
the previous exposure of ferrets to a contemporary sea-
sonal A/H1N1 influenza virus is capable of priming a
greater antibody response to a subsequent dose of a
non-adjuvanted monovalent pandemic A/H1N1/2009
influenza vaccine [15], but we found no significant dif-
ference in pandemic A/H1N1/2009 antibody levels
between our children who were positive for antibodies
against seasonal A/H1N1 infection and those who were
negative. It is possible that both these findings can be
explained by non-immunological factors. The lack of
any correlation between previous immunity against sea-
sonal A/H1N1/2009 influenza virus and severity of
influenza disease can simply be the consequence of an
age effect. Influenza is per se more severe in younger
patients (i.e., those less exposed to seasonal viruses) and
these characteristics have been clearly demonstrated also
for the recent pandemic [4,5]. Moreover, data collected
in experimental animals cannot be easily compared with
those found in humans because these are very little
homogeneous by age and sex and the global sample can
be potentially affected by a selection bias. However,
both these findings can be explained by means of the
so-called “antigenic sin phenomenon”, according to
which the relative absence of exposure to influenza virus
variants (as is usual in otherwise healthy children who
have not received an influenza vaccination) may pro-
mote viral spread, whereas multiple exposures to variant
viruses (as is usual in older people or subjects repeatedly
vaccinated against seasonal influenza) may engender
greater immune protection because of the immune sys-
tem’s capacity for cross-reactivity [16]. This hypothesis
is consistent with the findings of Laurie et al. [17], who
showed that ferrets previously exposed to repeated
infections due to seasonal influenza A viruses were sig-
nificantly more protected against pandemic A/H1N1/
2009 influenza virus than those exposed to a single
infection.
The antibody responses to pandemic A/H1N1/2009
influenza virus in our children were not influenced by
age, gender, previous immunity against seasonal A/
H1N1 influenza virus, viral load or the use of oseltami-
vir, but were significantly greater in the patients with
the most severe disease. Our viral load data conflict
Table 2 Association between high antibody titres against pandemic A/H1N1/2009 influenza virus (≥160) and other
variables
Variables Univariate OR (95% CI) Multivariate OR adjusted for all variables (95% CI)
Age (yrs)
<median value (4.5) 1 1
≥ median value 0.48 (0.18-1.28) 0.60 (0.18-1.98)
Gender 1 1
Female
Male 0.57 (0.21-1.53) 0.54 (0.14-2.00)
Hospitalisation
No 1 1
Yes 3.38 (1.49-10.61) 4.43 (1.55-14.16)
Pneumonia
No 1 1
Yes 4.54 (1.57-13.14) 5.92 (1.66-21.18)
Previous immunity against seasonal A/H1N1 influenza virus
<40 1 1
≥40 0.27 (0.09-0.81) 0.70 (0.17-2.93)
Viral load, log10 cp/mL
<median value (8.2) 1 1
≥ median value 1.79 (0.67-4.78) 1.78 (0.55-5.77)
Oseltamivir therapy
No 1 1
Yes 1.13 (0.55-4.43) 1.19 (0.61-4.76)
CI confidence interval, OR odds ratio
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with those reported by Hung et al. [14], who found a
strict correlation between convalescent neutralising anti-
body titres and viral load. However, it is difficult to eval-
uate the effect of viral load on the characteristics of
influenza because viral load peaks 1-2 days after symp-
tom onset [14,18], frequently before the patients attend
an Emergency Room and their nasopharyngeal secre-
tions are collected.
Our findings concerning oseltamivir are in line with
those of Hung et al. [14], and what has been demon-
strated in subjects suffering from seasonal influenza
[18,19]. These findings clearly show that antiviral treat-
ment does not affect the subsequent humoral immune
response to viral infection, and so it is unlikely to be
associated with a higher rate of recurrence or
reinfection.
Finally, our data regarding the greater immune
response of children with more severe disease are quite
similar to those found in adults by Mak et al. [12], and
further support the conclusion that the immune system
of healthy children seems capable of facing pandemic
influenza infection.
Conclusions
Despite collected in a relatively small number of
patients, our findings suggest that the immune response
of children after natural infection with pandemic A/
H1N1/2009 influenza virus evokes adequate seroprotec-
tion. The strength of the immune response seems to be
related to the severity of the disease, but not to previous
immunity against seasonal A/H1N1 influenza. However,
further studies are needed to determine how long effica-
cious antibody levels last and whether patients with the
poorest immune response may be affected by new epi-
sodes during the same influenza season.
Methods
Study patients
The study involved subjects aged less than 15 years
without any underlying chronic severe disease who
attended the Emergency Room or were hospitalised dur-
ing one of the two weeks of the peak period of pan-
demic A/H1N1v influenza in Italy (9-15 November
2009) because of an influenza-like illness as defined by
the Italian Ministry of Health http://http//www.minister-
osalute.it. This definition is an acute respiratory disease
of sudden onset and with fever (an axillary temperature
of >38°C), accompanied by at least one of the general
symptoms of headache, generalised malaise, a feverish
sensation (sweating and chills) or asthenia, and by at
least one of the respiratory symptoms of cough, pharyn-
godynia or nasal congestion.
The exclusion criteria were chronic diseases increasing
the risk of complications of viral respiratory infections,
including premature birth; chronic disorders of the pul-
monary or cardiovascular systems, including asthma;
chronic metabolic diseases, including diabetes mellitus;
neoplasia; kidney or liver dysfunction; hemoglobinopa-
thies; immunosuppression; diseases requiring long-term
aspirin therapy; and genetic or neurological disorders.
The enrolled patients’ demographic characteristics and
medical history were systematically recorded using stan-
dardised written questionnaires as previously described
[20,21] and, after a complete physical examination, they
were classified into disease groups on the basis of signs
and/or symptoms using well-established criteria [22].
Upon enrolment, a nasopharyngeal swab for the diagno-
sis of pandemic A/H1N1/2009 influenza infection was
collected from all of the children, as was a blood sample
for the evaluation of antibody levels against the pan-
demic A/H1N1/2009 and the seasonal A/H1N1 viruses
circulating in the previous two years.
The participants who were positive for pandemic A/
H1N1/2009 influenza infection were asked to return for
a final visit four weeks (28 ± 2 days) after enrolment,
during which clinical data were collected and a further
blood sample was drawn to determine anti-A/H1N1/
2009 antibody levels.
The study was approved by the Institutional Review
Board of the Fondazione IRCCS Ca’ Granda Ospedale
Maggiore Policlinico, Milan, Italy, and was carried out
in the Department of Maternal and Pediatric Sciences of
the University of Milan. The written informed consent
of a parent or legal guardian was required, and the older
children were asked to give their assent.
Laboratory assays
Each nasopharyngeal sample was obtained using a per-
nasal flocked swab, and stored in a tube of UTM-RT
(Kit Cat. No. 360c, Copan Italia, Brescia, Italy). Viral
RNA was extracted from the swabs by means of a
Nuclisens EasyMAG automated extraction system (Bio-
meriéux, Craponne, France). All of the samples were
tested for the detection and characterisation of pan-
demic A/H1N1/2009 influenza virus following the
WHO/CDC protocol [23]. A plasmid containing the
corresponding target viral sequence (kindly provided by
the Molecular Virology Unit, Fondazione IRCCS Policli-
nico San Matteo, Pavia, Italy) was used to quantify viral
load. Ten-fold plasmid serial dilutions ranging from 5 to
5 × 107 input copies were prepared to generate calibra-
tion curves, and run in parallel with the tested samples.
The cycle threshold (Ct) values of each dilution were
measured in duplicate and plotted against the logarithm
of their initial quantities. The copy numbers in each
clinical sample were derived from the regression line.
The quantitative results were expressed as RNA copy
number/mL of nasopharyngeal swab following data
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multiplication by 50. In order to evaluate reproducibility,
intra-assay and interassay standard deviations (SDs) and
coefficients of variation were calculated for each stan-
dard concentration within and between the individual
PCR runs.
A/H1N1/2009 and seasonal A/H1N1 antibody levels
were evaluated by measuring hemagglutination-inhibit-
ing (HI) antibodies using standard assays [24]. The
serum samples were tested in duplicate at an initial dilu-
tion of 1:10, and the HI antibody titres were expressed
as the reciprocal of the highest serum dilution that com-
pletely inhibited hemagglutination. GMTs were com-
puted by assigning a titre of 5 for the samples in which
antibodies were undetectable. A subject was considered
seroprotected if his/her HI titre was ≥40.
Statistical analysis
The continuous variables are presented as mean values
± standard deviation (SD), and the categorical variables
as numbers and percentages. The continuous data were
analysed using a non-parametric test (i.e. two-sided Wil-
coxon rank sum test) as they were not normally distrib-
uted (based on the Shapiro-Wilk statistic); the
categorical data were analysed using contingency tables
and the chi-squared or Fisher’s test, as appropriate.
The univariate and multivariate odds ratios (ORs) of
high antibody titres against pandemic A/H1N1v virus (i.
e. ≥160), and their 95% confidence intervals (CI), were
derived using unconditional multiple logistic regression
models. The multivariate model was calculated using
terms for age and gender, hospitalisation, a diagnosis of
pneumonia, immunity against A/H1N1 seasonal influ-
enza virus, A/H1N1/2009 viral load, and oseltamivir
therapy.
Abbreviations
(CI): Confidence intervals; (GMTs): Geometric mean titres; (HI):
Hemagglutination-inhibiting; (ORs): Odds ratios; (RT-PCR): Reverse-
transcriptase polymerase chain reaction; (SD): Standard deviation.
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